[VIEW] agent=M&A Counsel (Deal Lead) | scenario_id=76 | rounds=20

--- Round 0 ---
[R0.1] M&A Counsel (Deal Lead) (speak, public): Let's get started. We've got a tight timeline to close this deal by May 15, 2026. Can you both give me an update on your respective areas? Compliance & Investigations Lead, can you share the latest on the investigation findings and potential remediation efforts?
[R0.2] Compliance & Investigations Lead (speak, public): We've completed an initial review of 24 months of AP data, sampling 14,200 transactions with 32 keyword flags. We've identified 9 red-flag payments totaling $186,000, with 6 linked to Brazil customs clearance. Additionally, we've assessed the third-party intermediary posture and found 3 high-risk distributors, 2 of which lack written anti-bribery clauses. We're also responding to a customs audit letter dated Feb 12, 2026, with a response deadline in 15 days. On the remediation front, we're proposing to suspend 2 vendors immediately and deliver 90-minute training to 60 employees. We've also identified control gaps, including a gifts/hospitality register missing 17 entries and an approvals threshold set at $250. I'd like to understand the deal timeline and any constraints that might impact our remediation sequencing.
[R0.3] Finance Director (Corporate Risk & Finance) (speak, public): We've got significant financial implications to consider given the potential red flags identified. The acquisition is funded with a $200M term loan at SOFR +225 bps. Any delay in closing will cost us $120k per week in bridge commitment fees, with a maximum extension of 8 weeks. We also need to be mindful of our board calendar constraints - the next audit committee meeting is on April 10, 2026, and materials are due 7 days prior. I'd like to understand how the investigation findings and proposed remediation efforts might impact our closing timeline and whether there are any internal sensitivities around walking away from the deal.

--- Round 1 ---
[R1.1] M&A Counsel (Deal Lead) (speak, public): Compliance & Investigations Lead, your findings are concerning, particularly the red-flag payments and high-risk distributors. Can you help me understand the likelihood that these issues would trigger a government investigation before our target closing date of May 15, 2026? Additionally, how confident are you that your proposed remediation efforts can be implemented quickly enough to mitigate these risks? Finance Director (Corporate Risk & Finance), can you elaborate on how a potential delay in closing might impact our financing costs and any other financial implications we should be aware of?
[R1.2] Compliance & Investigations Lead (speak, public): To assess the likelihood of a government investigation before May 15, 2026, I'd say it's difficult to predict with certainty. However, given the customs audit letter dated Feb 12, 2026, with a response deadline in 15 days, there's an ongoing regulatory touchpoint that could potentially escalate into a broader investigation if not handled properly. Our proposed remediation efforts are designed to address the identified control gaps and high-risk distributors. We've planned to suspend 2 vendors immediately and deliver 90-minute training to 60 employees. While we can implement these measures quickly, the effectiveness will depend on various factors, including employee engagement and the vendors' cooperation. I'd like to understand the flexibility around the closing timeline and any potential internal financial preferences that might influence our decision.
[R1.3] Finance Director (Corporate Risk & Finance) (speak, private to=M&A Counsel (Deal Lead),Compliance & Investigations Lead): To better understand the financial implications of the potential red flags and the proposed remediation efforts, I'd like to share some information on our estimated downside exposure and insurance coverage. We've estimated the potential settlement range to be between $8M and $16M, with a probability-weighted midpoint of $11M. Our crime policy limit is $5M with a retention of $250k, but it excludes regulatory fines. Given the investigation findings, I'd like to understand how the proposed remediation efforts might impact our closing timeline and whether there are any internal sensitivities around walking away from the deal.

--- Round 2 ---
[R2.1] M&A Counsel (Deal Lead) (speak, public): Compliance & Investigations Lead, can you clarify how the proposed remediation efforts might impact our ability to meet the May 15, 2026 closing date, and whether there are any specific regulatory or compliance milestones we need to hit before then? Finance Director (Corporate Risk & Finance), given the estimated downside exposure and insurance coverage, can you help me understand how the company's risk tolerance might influence our decision on whether to proceed with the acquisition, delay it, or potentially renegotiate terms?
[R2.2] Compliance & Investigations Lead (speak, public): To clarify the impact of the proposed remediation efforts on our ability to meet the May 15, 2026 closing date, I'd say that we're working to implement the measures as quickly as possible. However, the effectiveness will depend on various factors, including employee engagement and the vendors' cooperation. We need to understand the flexibility around the closing timeline and any potential internal financial preferences that might influence our decision. I'd like to know if there's any room for maneuvering on the closing date or if there are any internal sensitivities around walking away from the deal or renegotiating terms.
[R2.3] Finance Director (Corporate Risk & Finance) (speak, public): To help assess the financial implications and potential next steps, I'd like to clarify that our current investigation spend is $180k against a FY26 cap of $600k, giving us remaining capacity to further investigate and potentially support remediation efforts. Given the estimated downside exposure and the insurance coverage boundaries I've previously shared, I'd like to understand from both of you whether the proposed remediation efforts are likely to be sufficient to mitigate the identified risks to an acceptable level, and how that assessment might influence our decision on whether to proceed with the acquisition as planned, delay it, or potentially renegotiate terms.

--- Round 3 ---
[R3.1] M&A Counsel (Deal Lead) (speak, public): To summarize, we're dealing with potential anti-corruption red flags at the target, including $186,000 in red-flag payments and high-risk distributors. The proposed remediation efforts are underway, but their effectiveness and timeline are uncertain. Financially, we're looking at a potential downside exposure with an estimated probability-weighted midpoint of $11M, and our insurance coverage has limitations. We need to assess whether to proceed with the acquisition as planned, delay it, or renegotiate terms. Compliance & Investigations Lead, can you confirm whether the proposed remediation efforts can be completed within our integration gating timeline, particularly the ERP cutover planned 30 days after close? Finance Director (Corporate Risk & Finance), how might our financing constraints, including the $120k per week in bridge commitment fees, influence our decision on whether to proceed, delay, or renegotiate?
[R3.2] Compliance & Investigations Lead (speak, public): To confirm whether the proposed remediation efforts can be completed within the integration gating timeline, particularly the ERP cutover planned 30 days after close, I'd say that we're working to implement the measures as quickly as possible. Our current plan includes suspending 2 vendors immediately and delivering 90-minute training to 60 employees. However, the effectiveness will depend on various factors, including employee engagement and the vendors' cooperation. We need to understand the flexibility around the closing timeline and any potential internal financial preferences that might influence our decision. I'd like to know if there's any room for maneuvering on the closing date or if there are any internal sensitivities around walking away from the deal or renegotiating terms.
[R3.3] Finance Director (Corporate Risk & Finance) (speak, public): To help assess the financial implications and potential next steps, I'd like to highlight that our current investigation spend is $180k against a FY26 cap of $600k, giving us remaining capacity to further investigate and potentially support remediation efforts. Given the estimated downside exposure and the insurance coverage boundaries I've previously shared, I'd like to understand from both of you whether the proposed remediation efforts are likely to be sufficient to mitigate the identified risks to an acceptable level, and how that assessment might influence our decision on whether to proceed with the acquisition as planned, delay it, or potentially renegotiate terms. Additionally, considering our financing constraints, including the $120k per week in bridge commitment fees and the board calendar constraint with the next audit committee meeting on April 10, 2026, I'd like to know if there are any internal sensitivities around walking away from the deal or renegotiating terms that we should be aware of.

--- Round 4 ---
[R4.1] M&A Counsel (Deal Lead) (speak, public): To summarize our discussion, we've identified significant anti-corruption red flags at the target, including $186,000 in red-flag payments and high-risk distributors. The proposed remediation efforts are underway, but their effectiveness and timeline are uncertain. Financially, we're looking at a potential downside exposure with an estimated probability-weighted midpoint of $11M, and our insurance coverage has limitations. Given these findings and the looming May 15, 2026 closing date, I'd like to confirm whether we have any flexibility to delay closing or renegotiate terms. Compliance & Investigations Lead, can you provide an update on the status of the customs audit response and any potential implications for our closing timeline? Finance Director (Corporate Risk & Finance), can you clarify how our financing constraints and risk tolerance might influence our decision on whether to proceed with the acquisition as planned, delay it, or potentially renegotiate terms?
[R4.2] Compliance & Investigations Lead (speak, public): To update on the status of the customs audit response, we've received the audit letter dated Feb 12, 2026, and we're working to respond within the 15-day deadline. The potential implications for our closing timeline are uncertain, but a negative response could potentially delay our closing or impact our ability to meet the May 15, 2026 target. I'd like to understand if there's any flexibility around the closing timeline and what internal financial preferences might influence our decision.
[R4.3] Finance Director (Corporate Risk & Finance) (speak, public): To help assess the financial implications and potential next steps, I'd like to highlight that our financing constraints, including the $120k per week in bridge commitment fees, and the board calendar constraint with the next audit committee meeting on April 10, 2026, are critical factors in our decision-making process. Given the estimated downside exposure and the insurance coverage boundaries previously shared, I'd like to understand from both of you whether the proposed remediation efforts are likely to be sufficient to mitigate the identified risks to an acceptable level, and how that assessment might influence our decision on whether to proceed with the acquisition as planned, delay it, or potentially renegotiate terms. Additionally, I'd appreciate any insights on internal sensitivities around walking away from the deal or renegotiating terms that we should be aware of.

--- Round 5 ---
[R5.1] M&A Counsel (Deal Lead) (speak, public): To summarize our discussion and assess our next steps, I'd like to confirm that we've identified significant anti-corruption red flags at the target, including $186,000 in red-flag payments and high-risk distributors. The proposed remediation efforts are underway, but their effectiveness and timeline are uncertain. Financially, we're looking at a potential downside exposure with an estimated probability-weighted midpoint of $11M, and our insurance coverage has limitations. Given these findings and the looming May 15, 2026 closing date, I'd like to ask: Compliance & Investigations Lead, can you provide an update on the status of the customs audit response and any potential implications for our closing timeline? Finance Director (Corporate Risk & Finance), can you clarify how our financing constraints and risk tolerance might influence our decision on whether to proceed with the acquisition as planned, delay it, or potentially renegotiate terms?
[R5.2] Compliance & Investigations Lead (speak, public): To update on the status of the customs audit response, we've received the audit letter dated Feb 12, 2026, and we're working to respond within the 15-day deadline. The potential implications for our closing timeline are uncertain, but a negative response could potentially delay our closing or impact our ability to meet the May 15, 2026 target. I'd like to understand if there's any flexibility around the closing timeline and what internal financial preferences might influence our decision.
[R5.3] Finance Director (Corporate Risk & Finance) (speak, public): To help assess the financial implications and potential next steps, I'd like to highlight that our financing constraints, including the $120k per week in bridge commitment fees, and the board calendar constraint with the next audit committee meeting on April 10, 2026, are critical factors in our decision-making process. Given the estimated downside exposure and the insurance coverage boundaries previously shared, I'd like to understand from both of you whether the proposed remediation efforts are likely to be sufficient to mitigate the identified risks to an acceptable level, and how that assessment might influence our decision on whether to proceed with the acquisition as planned, delay it, or potentially renegotiate terms. Additionally, I'd appreciate any insights on internal sensitivities around walking away from the deal or renegotiating terms that we should be aware of.

--- Round 6 ---
[R6.1] M&A Counsel (Deal Lead) (speak, public): To summarize our discussion and assess our next steps, we've identified significant anti-corruption red flags at the target, including $186,000 in red-flag payments and high-risk distributors. The proposed remediation efforts are underway, but their effectiveness and timeline are uncertain. Financially, we're looking at a potential downside exposure with an estimated probability-weighted midpoint of $11M, and our insurance coverage has limitations. Given these findings and the looming May 15, 2026 closing date, I'd like to ask: Compliance & Investigations Lead, can you confirm if the proposed remediation efforts can be completed within our integration gating timeline? Finance Director (Corporate Risk & Finance), can you clarify how our financing constraints might influence our decision?
[R6.2] Compliance & Investigations Lead (speak, public): To confirm whether the proposed remediation efforts can be completed within our integration gating timeline, particularly the ERP cutover planned 30 days after close, I'd say that we're working to implement the measures as quickly as possible. Our current plan includes suspending 2 vendors immediately and delivering 90-minute training to 60 employees. However, the effectiveness will depend on various factors, including employee engagement and the vendors' cooperation. We need to understand the flexibility around the closing timeline and any potential internal financial preferences that might influence our decision. I'd like to know if there's any room for maneuvering on the closing date or if there are any internal sensitivities around walking away from the deal or renegotiating terms.
[R6.3] Finance Director (Corporate Risk & Finance) (speak, public): To help assess the financial implications and potential next steps, I'd like to highlight that our financing constraints, including the $120k per week in bridge commitment fees, and the board calendar constraint with the next audit committee meeting on April 10, 2026, are critical factors in our decision-making process. Given the estimated downside exposure and the insurance coverage boundaries previously shared, I'd like to understand from both of you whether the proposed remediation efforts are likely to be sufficient to mitigate the identified risks to an acceptable level, and how that assessment might influence our decision on whether to proceed with the acquisition as planned, delay it, or potentially renegotiate terms. Additionally, I'd appreciate any insights on internal sensitivities around walking away from the deal or renegotiating terms that we should be aware of.

--- Round 7 ---
[R7.1] M&A Counsel (Deal Lead) (speak, public): To summarize our discussion and assess our next steps, we've identified significant anti-corruption red flags at the target, including $186,000 in red-flag payments and high-risk distributors. The proposed remediation efforts are underway, but their effectiveness and timeline are uncertain. Financially, we're looking at a potential downside exposure with an estimated probability-weighted midpoint of $11M, and our insurance coverage has limitations. Given these findings and the looming May 15, 2026 closing date, I'd like to ask: Compliance & Investigations Lead, can you confirm if the proposed remediation efforts can be completed within our integration gating timeline, particularly the ERP cutover planned 30 days after close? Finance Director (Corporate Risk & Finance), can you clarify how our financing constraints might influence our decision?
[R7.2] Compliance & Investigations Lead (speak, public): To confirm whether the proposed remediation efforts can be completed within our integration gating timeline, particularly the ERP cutover planned 30 days after close, I'd say that we're working to implement the measures as quickly as possible. Our current plan includes suspending 2 vendors immediately and delivering 90-minute training to 60 employees. However, the effectiveness will depend on various factors, including employee engagement and the vendors' cooperation. We need to understand the flexibility around the closing timeline and any potential internal financial preferences that might influence our decision. I'd like to know if there's any room for maneuvering on the closing date or if there are any internal sensitivities around walking away from the deal or renegotiating terms.
[R7.3] Finance Director (Corporate Risk & Finance) (speak, public): To help assess the financial implications and potential next steps, I'd like to highlight that our financing constraints, including the $120k per week in bridge commitment fees, and the board calendar constraint with the next audit committee meeting on April 10, 2026, are critical factors in our decision-making process. Given the estimated downside exposure and the insurance coverage boundaries previously shared, I'd like to understand from both of you whether the proposed remediation efforts are likely to be sufficient to mitigate the identified risks to an acceptable level, and how that assessment might influence our decision on whether to proceed with the acquisition as planned, delay it, or potentially renegotiate terms. Additionally, I'd appreciate any insights on internal sensitivities around walking away from the deal or renegotiating terms that we should be aware of.

--- Round 8 ---
[R8.1] M&A Counsel (Deal Lead) (speak, public): To summarize our discussion and assess our next steps, we've identified significant anti-corruption red flags at the target, including $186,000 in red-flag payments and high-risk distributors. The proposed remediation efforts are underway, but their effectiveness and timeline are uncertain. Financially, we're looking at a potential downside exposure with an estimated probability-weighted midpoint of $11M, and our insurance coverage has limitations. Given these findings and the looming May 15, 2026 closing date, I'd like to ask: Compliance & Investigations Lead, can you confirm if the proposed remediation efforts can be completed within our integration gating timeline, particularly the ERP cutover planned 30 days after close? Finance Director (Corporate Risk & Finance), can you clarify how our financing constraints might influence our decision?
[R8.2] Compliance & Investigations Lead (speak, public): To confirm whether the proposed remediation efforts can be completed within our integration gating timeline, particularly the ERP cutover planned 30 days after close, I'd say that we're working to implement the measures as quickly as possible. Our current plan includes suspending 2 vendors immediately and delivering 90-minute training to 60 employees. However, the effectiveness will depend on various factors, including employee engagement and the vendors' cooperation. We need to understand the flexibility around the closing timeline and any potential internal financial preferences that might influence our decision. I'd like to know if there's any room for maneuvering on the closing date or if there are any internal sensitivities around walking away from the deal or renegotiating terms.
[R8.3] Finance Director (Corporate Risk & Finance) (speak, public): To help assess the financial implications and potential next steps, I'd like to highlight that our financing constraints, including the $120k per week in bridge commitment fees, and the board calendar constraint with the next audit committee meeting on April 10, 2026, are critical factors in our decision-making process. Given the estimated downside exposure and the insurance coverage boundaries previously shared, I'd like to understand from both of you whether the proposed remediation efforts are likely to be sufficient to mitigate the identified risks to an acceptable level, and how that assessment might influence our decision on whether to proceed with the acquisition as planned, delay it, or potentially renegotiate terms. Additionally, I'd appreciate any insights on internal sensitivities around walking away from the deal or renegotiating terms that we should be aware of.

--- Round 9 ---
[R9.1] M&A Counsel (Deal Lead) (speak, public): To summarize our discussion and assess our next steps, we've identified significant anti-corruption red flags at the target, including $186,000 in red-flag payments and high-risk distributors. The proposed remediation efforts are underway, but their effectiveness and timeline are uncertain. Financially, we're looking at a potential downside exposure with an estimated probability-weighted midpoint of $11M, and our insurance coverage has limitations. Given these findings and the looming May 15, 2026 closing date, I'd like to ask: Compliance & Investigations Lead, can you confirm if the proposed remediation efforts can be completed within our integration gating timeline, particularly the ERP cutover planned 30 days after close? Finance Director (Corporate Risk & Finance), can you clarify how our financing constraints might influence our decision?
[R9.2] Compliance & Investigations Lead (speak, public): To confirm whether the proposed remediation efforts can be completed within our integration gating timeline, particularly the ERP cutover planned 30 days after close, I'd say that we're working to implement the measures as quickly as possible. Our current plan includes suspending 2 vendors immediately and delivering 90-minute training to 60 employees. However, the effectiveness will depend on various factors, including employee engagement and the vendors' cooperation. We need to understand the flexibility around the closing timeline and any potential internal financial preferences that might influence our decision. I'd like to know if there's any room for maneuvering on the closing date or if there are any internal sensitivities around walking away from the deal or renegotiating terms.
[R9.3] Finance Director (Corporate Risk & Finance) (speak, public): To help assess the financial implications and potential next steps, I'd like to highlight that our financing constraints, including the $120k per week in bridge commitment fees, and the board calendar constraint with the next audit committee meeting on April 10, 2026, are critical factors in our decision-making process. Given the estimated downside exposure and the insurance coverage boundaries previously shared, I'd like to understand from both of you whether the proposed remediation efforts are likely to be sufficient to mitigate the identified risks to an acceptable level, and how that assessment might influence our decision on whether to proceed with the acquisition as planned, delay it, or potentially renegotiate terms. Additionally, I'd appreciate any insights on internal sensitivities around walking away from the deal or renegotiating terms that we should be aware of.

--- Round 10 ---
[R10.1] M&A Counsel (Deal Lead) (speak, public): To summarize our discussion and assess our next steps, we've identified significant anti-corruption red flags at the target, including $186,000 in red-flag payments and high-risk distributors. The proposed remediation efforts are underway, but their effectiveness and timeline are uncertain. Financially, we're looking at a potential downside exposure with an estimated probability-weighted midpoint of $11M, and our insurance coverage has limitations. Given these findings and the looming May 15, 2026 closing date, I'd like to ask: Compliance & Investigations Lead, can you confirm if the proposed remediation efforts can be completed within our integration gating timeline, particularly the ERP cutover planned 30 days after close? Finance Director (Corporate Risk & Finance), can you clarify how our financing constraints might influence our decision?
[R10.2] Compliance & Investigations Lead (speak, public): To confirm whether the proposed remediation efforts can be completed within our integration gating timeline, particularly the ERP cutover planned 30 days after close, I'd say that we're working to implement the measures as quickly as possible. Our current plan includes suspending 2 vendors immediately and delivering 90-minute training to 60 employees. However, the effectiveness will depend on various factors, including employee engagement and the vendors' cooperation. We need to understand the flexibility around the closing timeline and any potential internal financial preferences that might influence our decision. I'd like to know if there's any room for maneuvering on the closing date or if there are any internal sensitivities around walking away from the deal or renegotiating terms.
[R10.3] Finance Director (Corporate Risk & Finance) (speak, public): To help assess the financial implications and potential next steps, I'd like to highlight that our financing constraints, including the $120k per week in bridge commitment fees, and the board calendar constraint with the next audit committee meeting on April 10, 2026, are critical factors in our decision-making process. Given the estimated downside exposure and the insurance coverage boundaries previously shared, I'd like to understand from both of you whether the proposed remediation efforts are likely to be sufficient to mitigate the identified risks to an acceptable level, and how that assessment might influence our decision on whether to proceed with the acquisition as planned, delay it, or potentially renegotiate terms. Additionally, I'd appreciate any insights on internal sensitivities around walking away from the deal or renegotiating terms that we should be aware of.

--- Round 11 ---
[R11.1] M&A Counsel (Deal Lead) (speak, public): To summarize our discussion and assess our next steps, we've identified significant anti-corruption red flags at the target, including $186,000 in red-flag payments and high-risk distributors. The proposed remediation efforts are underway, but their effectiveness and timeline are uncertain. Financially, we're looking at a potential downside exposure with an estimated probability-weighted midpoint of $11M, and our insurance coverage has limitations. Given these findings and the looming May 15, 2026 closing date, I'd like to ask: Compliance & Investigations Lead, can you confirm if the proposed remediation efforts can be completed within our integration gating timeline, particularly the ERP cutover planned 30 days after close? Finance Director (Corporate Risk & Finance), can you clarify how our financing constraints might influence our decision?
[R11.2] Compliance & Investigations Lead (speak, public): To confirm whether the proposed remediation efforts can be completed within our integration gating timeline, particularly the ERP cutover planned 30 days after close, I'd say that we're working to implement the measures as quickly as possible. Our current plan includes suspending 2 vendors immediately and delivering 90-minute training to 60 employees. However, the effectiveness will depend on various factors, including employee engagement and the vendors' cooperation. We need to understand the flexibility around the closing timeline and any potential internal financial preferences that might influence our decision. I'd like to know if there's any room for maneuvering on the closing date or if there are any internal sensitivities around walking away from the deal or renegotiating terms.
[R11.3] Finance Director (Corporate Risk & Finance) (speak, public): To help assess the financial implications and potential next steps, I'd like to highlight that our financing constraints, including the $120k per week in bridge commitment fees, and the board calendar constraint with the next audit committee meeting on April 10, 2026, are critical factors in our decision-making process. Given the estimated downside exposure and the insurance coverage boundaries previously shared, I'd like to understand from both of you whether the proposed remediation efforts are likely to be sufficient to mitigate the identified risks to an acceptable level, and how that assessment might influence our decision on whether to proceed with the acquisition as planned, delay it, or potentially renegotiate terms. Additionally, I'd appreciate any insights on internal sensitivities around walking away from the deal or renegotiating terms that we should be aware of.

--- Round 12 ---
[R12.1] M&A Counsel (Deal Lead) (speak, public): To summarize our discussion and assess our next steps, we've identified significant anti-corruption red flags at the target, including $186,000 in red-flag payments and high-risk distributors. The proposed remediation efforts are underway, but their effectiveness and timeline are uncertain. Financially, we're looking at a potential downside exposure with an estimated probability-weighted midpoint of $11M, and our insurance coverage has limitations. Given these findings and the looming May 15, 2026 closing date, I'd like to ask: Compliance & Investigations Lead, can you confirm if the proposed remediation efforts can be completed within our integration gating timeline, particularly the ERP cutover planned 30 days after close? Finance Director (Corporate Risk & Finance), can you clarify how our financing constraints might influence our decision?
[R12.2] Compliance & Investigations Lead (speak, public): To confirm whether the proposed remediation efforts can be completed within our integration gating timeline, particularly the ERP cutover planned 30 days after close, I'd say that we're working to implement the measures as quickly as possible. Our current plan includes suspending 2 vendors immediately and delivering 90-minute training to 60 employees. However, the effectiveness will depend on various factors, including employee engagement and the vendors' cooperation. We need to understand the flexibility around the closing timeline and any potential internal financial preferences that might influence our decision. I'd like to know if there's any room for maneuvering on the closing date or if there are any internal sensitivities around walking away from the deal or renegotiating terms.
[R12.3] Finance Director (Corporate Risk & Finance) (speak, public): To help assess the financial implications and potential next steps, I'd like to highlight that our financing constraints, including the $120k per week in bridge commitment fees, and the board calendar constraint with the next audit committee meeting on April 10, 2026, are critical factors in our decision-making process. Given the estimated downside exposure and the insurance coverage boundaries previously shared, I'd like to understand from both of you whether the proposed remediation efforts are likely to be sufficient to mitigate the identified risks to an acceptable level, and how that assessment might influence our decision on whether to proceed with the acquisition as planned, delay it, or potentially renegotiate terms. Additionally, I'd appreciate any insights on internal sensitivities around walking away from the deal or renegotiating terms that we should be aware of.

--- Round 13 ---
[R13.1] M&A Counsel (Deal Lead) (speak, public): To summarize our discussion and assess our next steps, we've identified significant anti-corruption red flags at the target, including $186,000 in red-flag payments and high-risk distributors. The proposed remediation efforts are underway, but their effectiveness and timeline are uncertain. Financially, we're looking at a potential downside exposure with an estimated probability-weighted midpoint of $11M, and our insurance coverage has limitations. Given these findings and the looming May 15, 2026 closing date, I'd like to ask: Compliance & Investigations Lead, can you confirm if the proposed remediation efforts can be completed within our integration gating timeline, particularly the ERP cutover planned 30 days after close? Finance Director (Corporate Risk & Finance), can you clarify how our financing constraints might influence our decision?
[R13.2] Compliance & Investigations Lead (speak, public): To confirm whether the proposed remediation efforts can be completed within our integration gating timeline, particularly the ERP cutover planned 30 days after close, I'd say that we're working to implement the measures as quickly as possible. Our current plan includes suspending 2 vendors immediately and delivering 90-minute training to 60 employees. However, the effectiveness will depend on various factors, including employee engagement and the vendors' cooperation. We need to understand the flexibility around the closing timeline and any potential internal financial preferences that might influence our decision. I'd like to know if there's any room for maneuvering on the closing date or if there are any internal sensitivities around walking away from the deal or renegotiating terms.
[R13.3] Finance Director (Corporate Risk & Finance) (speak, public): To help assess the financial implications and potential next steps, I'd like to highlight that our financing constraints, including the $120k per week in bridge bridgebridge commitment fees, and the board calendar constraint with the next audit committee meeting on April 10, 2026, are critical factors in our decision-making process. Given the estimated downside exposure and the insurance coverage boundaries previously shared, I'd like to understand from both of you whether the proposed remediation efforts are likely to be sufficient to mitigate the identified risks to an acceptable level, and how that assessment might influence our decision on whether to proceed with the acquisition as planned, delay it, or potentially renegotiate terms. Additionally, I'd appreciate any insights on internal sensitivities around walking away from the deal or renegotiating terms that we should be aware of.

--- Round 14 ---
[R14.1] M&A Counsel (Deal Lead) (speak, public): To summarize our discussion and assess our next steps, we've identified significant anti-corruption red flags at the target, including $186,000 in red-flag payments and high-risk distributors. The proposed remediation efforts are underway, but their effectiveness and timeline are uncertain. Financially, we're looking at a potential downside exposure with an estimated probability-weighted midpoint of $11M, and our insurance coverage has limitations. Given these findings and the looming May 15, 2026 closing date, I'd like to ask: Compliance & Investigations Lead, can you confirm if the proposed remediation efforts can be completed within our integration gating timeline, particularly the ERP cutover planned 30 days after close? Finance Director (Corporate Risk & Finance), can you clarify how our financing constraints might influence our decision?
[R14.2] Compliance & Investigations Lead (speak, public): To confirm whether the proposed remediation efforts can be completed within our integration gating timeline, particularly the ERP cutover planned 30 days after close, I'd say that we're working to implement the measures as quickly as possible. Our current plan includes suspending 2 vendors immediately and delivering 90-minute training to 60 employees. However, the effectiveness will depend on various factors, including employee engagement and the vendors' cooperation. We need to understand the flexibility around the closing timeline and any potential internal financial preferences that might influence our decision. I'd like to know if there's any room for maneuvering on the closing date or if there are any internal sensitivities around walking away from the deal or renegotiating terms.
[R14.3] Finance Director (Corporate Risk & Finance) (speak, public): To help assess the financial implications and potential next steps, I'd like to highlight that our financing constraints, including the $120k per week in bridge commitment fees, and the board calendar constraint with the next audit committee meeting on April 10, 2026, are critical factors in our decision-making process. Given the estimated downside exposure and the insurance coverage boundaries previously shared, I'd like to understand from both of you whether the proposed remediation efforts are likely to be sufficient to mitigate the identified risks to an acceptable level, and how that assessment might influence our decision on whether to proceed with the acquisition as planned, delay it, or potentially renegotiate terms. Additionally, I'd appreciate any insights on internal sensitivities around walking away from the deal or renegotiating terms that we should be aware of.

--- Round 15 ---
[R15.1] M&A Counsel (Deal Lead) (speak, public): To summarize our discussion and assess our next steps, we've identified significant anti-corruption red flags at the target, including $186,000 in red-flag payments and high-risk distributors. The proposed remediation efforts are underway, but their effectiveness and timeline are uncertain. Financially, we're looking at a potential downside exposure with an estimated probability-weighted midpoint of $11M, and our insurance coverage has limitations. Given these findings and the looming May 15, 2026 closing date, I'd like to ask: Compliance & Investigations Lead, can you confirm if the proposed remediation efforts can be completed within our integration gating timeline, particularly the ERP cutover planned 30 days after close? Finance Director (Corporate Risk & Finance), can you clarify how our financing constraints might influence our decision?
[R15.2] Compliance & Investigations Lead (speak, public): To confirm whether the proposed remediation efforts can be completed within our integration gating timeline, particularly the ERP cutover planned 30 days after close, I'd say that we're working to implement the measures as quickly as possible. Our current plan includes suspending 2 vendors immediately and delivering 90-minute training to 60 employees. However, the effectiveness will depend on various factors, including employee engagement and the vendors' cooperation. We need to understand the flexibility around the closing timeline and any potential internal financial preferences that might influence our decision. I'd like to know if there's any room for maneuvering on the closing date or if there are any internal sensitivities around walking away from the deal or renegotiating terms.
[R15.3] Finance Director (Corporate Risk & Finance) (speak, public): To help assess the financial implications and potential next steps, I'd like to highlight that our financing constraints, including the $120k per week in bridge commitment fees, and the board calendar constraint with the next audit committee meeting on April 10, 2026, are critical factors in our decision-making process. Given the estimated downside exposure and the insurance coverage boundaries previously shared, I'd like to understand from both of you whether the proposed remediation efforts are likely to be sufficient to mitigate the identified risks to an acceptable level, and how that assessment might influence our decision on whether to proceed with the acquisition as planned, delay it, or potentially renegotiate terms. Additionally, I'd appreciate any insights on internal sensitivities around walking away from the deal or renegotiating terms that we should be aware of.

--- Round 16 ---
[R16.1] M&A Counsel (Deal Lead) (speak, public): To summarize our discussion and assess our next steps, we've identified significant anti-corruption red flags at the target, including $186,000 in red-flag payments and high-risk distributors. The proposed remediation efforts are underway, but their effectiveness and timeline are uncertain. Financially, we're looking at a potential downside exposure with an estimated probability-weighted midpoint of $11M, and our insurance coverage has limitations. Given these findings and the looming May 15, 2026 closing date, I'd like to ask: Compliance & Investigations Lead, can you confirm if the proposed remediation efforts can be completed within our integration gating timeline, particularly the ERP cutover planned 30 days after close? Finance Director (Corporate Risk & Finance), can you clarify how our financing constraints might influence our decision?
[R16.2] Compliance & Investigations Lead (speak, public): To confirm whether the proposed remediation efforts can be completed within our integration gating timeline, particularly the ERP cutover planned 30 days after close, I'd say that we're working to implement the measures as quickly as possible. Our current plan includes suspending 2 vendors immediately and delivering 90-minute training to 60 employees. However, the effectiveness will depend on various factors, including employee engagement and the vendors' cooperation. We need to understand the flexibility around the closing timeline and any potential internal financial preferences that might influence our decision. I'd like to know if there's any room for maneuvering on the closing date or if there are any internal sensitivities around walking away from the deal or renegotiating terms.
[R16.3] Finance Director (Corporate Risk & Finance) (speak, public): To help assess the financial implications and potential next steps, I'd like to highlight that our financing constraints, including the $120k per week in bridge commitment fees, and the board calendar constraint with the next audit committee meeting on April 10, 2026, are critical factors in our decision-making process. Given the estimated downside exposure and the insurance coverage boundaries previously shared, I'd like to understand from both of you whether the proposed remediation efforts are likely to be sufficient to mitigate the identified risks to an acceptable level, and how that assessment might influence our decision on whether to proceed with the acquisition as planned, delay it, or potentially renegotiate terms. Additionally, I'd appreciate any insights on internal sensitivities around walking away from the deal or renegotiating terms that we should be aware of.

--- Round 17 ---
[R17.1] M&A Counsel (Deal Lead) (speak, public): To summarize our discussion and assess our next steps, we've identified significant anti-corruption red flags at the target, including $186,000 in red-flag payments and high-risk distributors. The proposed remediation efforts are underway, but their effectiveness and timeline are uncertain. Financially, we're looking at a potential downside exposure with an estimated probability-weighted midpoint of $11M, and our insurance coverage has limitations. Given these findings and the looming May 15, 2026 closing date, I'd like to ask: Compliance & Investigations Lead, can you confirm if the proposed remediation efforts can be completed within our integration gating timeline, particularly the ERP cutover planned 30 days after close? Finance Director (Corporate Risk & Finance), can you clarify how our financing constraints might influence our decision?
[R17.2] Compliance & Investigations Lead (speak, public): To confirm whether the proposed remediation efforts can be completed within our integration gating timeline, particularly the ERP cutover planned 30 days after close, I'd say that we're working to implement the measures as quickly as possible. Our current plan includes suspending 2 vendors immediately and delivering 90-minute training to 60 employees. However, the effectiveness will depend on various factors, including employee engagement and the vendors' cooperation. We need to understand the flexibility around the closing timeline and any potential internal financial preferences that might influence our decision. I'd like to know if there's any room for maneuvering on the closing date or if there are any internal sensitivities around walking away from the deal or renegotiating terms.
[R17.3] Finance Director (Corporate Risk & Finance) (speak, public): To help assess the financial implications and potential next steps, I'd like to highlight that our financing constraints, including the $120k per week in bridge commitment fees, and the board calendar constraint with the next audit committee meeting on April 10, 2026, are critical factors in our decision-making process. Given the estimated downside exposure and the insurance coverage boundaries previously shared, I'd like to understand from both of you whether the proposed remediation efforts are likely to be sufficient to mitigate the identified risks to an acceptable level, and how that assessment might influence our decision on whether to proceed with the acquisition as planned, delay it, or potentially renegotiate terms. Additionally, I'd appreciate any insights on internal sensitivities around walking away from the deal or renegotiating terms that we should be aware of.

--- Round 18 ---
[R18.1] M&A Counsel (Deal Lead) (speak, public): To summarize our discussion and assess our next steps, we've identified significant anti-corruption red flags at the target, including $186,000 in red-flag payments and high-risk distributors. The proposed remediation efforts are underway, but their effectiveness and timeline are uncertain. Financially, we're looking at a potential downside exposure with an estimated probability-weighted midpoint of $11M, and our insurance coverage has limitations. Given these findings and the looming May 15, 2026 closing date, I'd like to ask: Compliance & Investigations Lead, can you confirm if the proposed remediation efforts can be completed within our integration gating timeline, particularly the ERP cutover planned 30 days after close? Finance Director (Corporate Risk & Finance), can you clarify how our financing constraints might influence our decision?
[R18.2] Compliance & Investigations Lead (speak, public): To confirm whether the proposed remediation efforts can be completed within our integration gating timeline, particularly the ERP cutover planned 30 days after close, I'd say that we're working to implement the measures as quickly as possible. Our current plan includes suspending 2 vendors immediately and delivering 90-minute training to 60 employees. However, the effectiveness will depend on various factors, including employee engagement and the vendors' cooperation. We need to understand the flexibility around the closing timeline and any potential internal financial preferences that might influence our decision. I'd like to know if there's any room for maneuvering on the closing date or if there are any internal sensitivities around walking away from the deal or renegotiating terms.
[R18.3] Finance Director (Corporate Risk & Finance) (speak, public): To help assess the financial implications and potential next steps, I'd like to highlight that our financing constraints, including the $120k per week in bridge commitment fees, and the board calendar constraint with the next audit committee meeting on April 10, 2026, are critical factors in our decision-making process. Given the estimated downside exposure and the insurance coverage boundaries previously shared, I'd like to understand from both of you whether the proposed remediation efforts are likely to be sufficient to mitigate the identified risks to an acceptable level, and how that assessment might influence our decision on whether to proceed with the acquisition as planned, delay it, or potentially renegotiate terms. Additionally, I'd appreciate any insights on internal sensitivities around walking away from the deal or renegotiating terms that we should be aware of.

--- Round 19 ---
[R19.1] M&A Counsel (Deal Lead) (speak, public): To summarize our discussion and assess our next steps, we've identified significant anti-corruption red flags at the target, including $186,000 in red-flag payments and high-risk distributors. The proposed remediation efforts are underway, but their effectiveness and timeline are uncertain. Financially, we're looking at a potential downside exposure with an estimated probability-weighted midpoint of $11M, and our insurance coverage has limitations. Given these findings and the looming May 15, 2026 closing date, I'd like to ask: Compliance & Investigations Lead, can you confirm if the proposed remediation efforts can be completed within our integration gating timeline, particularly the ERP cutover planned 30 days after close? Finance Director (Corporate Risk & Finance), can you clarify how our financing constraints might influence our decision?
[R19.2] Compliance & Investigations Lead (speak, public): To confirm whether the proposed remediation efforts can be completed within our integration gating timeline, particularly the ERP cutover planned 30 days after close, I'd say that we're working to implement the measures as quickly as possible. Our current plan includes suspending 2 vendors immediately and delivering 90-minute training to 60 employees. However, the effectiveness will depend on various factors, including employee engagement and the vendors' cooperation. We need to understand the flexibility around the closing timeline and any potential internal financial preferences that might influence our decision. I'd like to know if there's any room for maneuvering on the closing date or if there are any internal sensitivities around walking away from the deal or renegotiating terms.
[R19.3] Finance Director (Corporate Risk & Finance) (speak, public): To help assess the financial implications and potential next steps, I'd like to highlight that our financing constraints, including the $120k per week in bridge commitment fees, and the board calendar constraint with the next audit committee meeting on April 10, 2026, are critical factors in our decision-making process. Given the estimated downside exposure and the insurance coverage boundaries previously shared, I'd like to understand from both of you whether the proposed remediation efforts are likely to be sufficient to mitigate the identified risks to an acceptable level, and how that assessment might influence our decision on whether to proceed with the acquisition as planned, delay it, or potentially renegotiate terms. Additionally, I'd appreciate any insights on internal sensitivities around walking away from the deal or renegotiating terms that we should be aware of.

